Industry News
Epitan partners with pSivida in tanning drug project
A safe tan in a single injection is the aim of a new collaborative agreement between two Australian biotechnology companies. [ + ]
Peptech gets green light for dog contraceptive
Sydney peptide and protein therapeutics developer Peptech Ltd (ASX:PTD ) has announced that its fully owned subsidiary, Peptech Animal Health (PAH) has received approval to market its Suprelorin six-month contraceptive for dogs in Australia. [ + ]
Going for gold with nanotechnology
Collaborative nanotechnology research involving the University of Technology, Sydney has proved the value of gold as a vital component in the next generation of electronics.
[ + ]ATP Innovations signs MoU with CSU, Wagga Wagga
Technology business commercialisation centre ATP Innovations has entered an agreement with Charles Sturt University and Wagga Wagga City Council to help put research on the track to market. [ + ]
Blis Technologies aims at Chinese market
Dunedin (NZ) biotech company Blis Technologies has opened a portal into a potential $200 million market by signing a deal with Auckland-based Asia Pacific Biotech Distributors (APBD) to take its antibacterial Throat Guard into China. [ + ]
Acrux in major deal with Eli Lilly
Melbourne drug delivery systems developer Acrux has signed a major deal with global pharmaceutical group Eli Lilly and Company to commercialise its veterinary product line. [ + ]
New study to explore genetics of eczema
A tri-state research collaboration is set to use sibling pairs to examine the genetic reasoning behind the most common form of eczema [ + ]
CSIRO livestock researchers explore potential of new technologies
Two animal-virus hunters at CSIRO are exploring the potential of advanced genetic and proteomics technologies to make more accurate and rapid diagnoses of viral diseases and other microbial infections of livestock. [ + ]
Virax raises $3.4m
Development-stage biotechnology company Virax Holdings (ASX: VHL) has raised $3.4 million in a capital raising aimed to progress its prostate cancer and HIV drug development programs. [ + ]
New CEO at Peplin Biotech
Brisbane small molecule drug development company Peplin Biotech (ASX: PEP) today announced the appointment of its new chief executive. [ + ]
Burying the problem of greenhouse emissions
More than half of Australia's carbon dioxide emissions come from power stations. Storing these harmful gases underground can drastically reduce the rate of emission build-up in our atmosphere.
[ + ]History offers modern slant on bioethics
University of Queensalnd historian Dr Sarah Ferber is redefining contemporary bioethics to include a historical dimension. And she's planning a book exploring topics such as medicine and social morality, human experimentation, women and reproductive medicine, genetic research and euthanasia.
[ + ]WEHI team exposes two new anti-cancer targets
Cancer researchers in Melbourne and Innsbruck hunting for new options to treat cancer have flushed two promising new therapeutic targets from the genetic thickets of the p53-mediated apoptosis pathway: Puma and Noxa. [ + ]
Hunter research labs team with Amersham in new project
The University of Newcastle and the Hunter Medical Research Institute have linked up with international life sciences supply company Amersham BioSciences to establish a sophisticated analytical laboratory for research into personalised medicine. [ + ]
Diabetes researcher Zimmett honoured
Diabetes luminary Prof Paul Zimmet has been honoured by his peers, receiving the Kellion Award for his contribution to the field. [ + ]
